Basic Science Workshop - Stars at Night Ballroom 3&4
Moderator: Alana L. Welm, PhD
University of Utah
Salt Lake City, UT

APOBEC and genome evolution in mBC
Reuben S. Harris, PhD
UT Health San Antonio
San Antonio, TX

Therapy-induced senescence: Friend or foe?
Sheila Stewart, PhD
Washington University
St. Louis, MO

Drug-tolerant persister cells in cancer
Joan S. Brugge, PhD
Harvard Medical School
Boston, MA

Clinical implications of tumor heterogeneity single cell genomics
Nnennaya Kanu, PhD
University College London, Cancer Institute
London, United Kingdom

EDUCATIONAL SESSION BLOCK #1

Educational Session Block #1A - Stars at Night Ballroom 3&4
Living with Metastatic Breast Cancer
Moderator: Anne Blaes, MD
University of Minnesota
Minneapolis, MN

Early palliative care
Tara L. Kaufmann, MD, MSCE
University of Texas at Austin
Austin, TX

Support for patients with MBC
Abbey Kaler, NP
UT MD Anderson Cancer Center
Houston, TX

Financial Toxicity
Fumiko Chino, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Patient Perspective
Christine Hodgdon
GRASP - Guiding Researchers & Advocates to Scientific Partnerships
Baltimore, MD

Stephanie Walker
MBC Alliance
Tarboro, NC

EDUCATIONAL SESSION BLOCK #1B - Hemisfair Ballroom 1&2
Local Therapy - Best Breast Practice
Moderator: Peter Dubsky, MD, PhD
Breast Center Hirslanden Klinik St. Anna
Luzem, Switzerland

Contralateral mastectomy in patients with germline mutations
Katharine A. Yao, MD
Northshore University HealthSystem
Evanston, IL

RT: How short can it be
David Krug, Dr Med
Universitätsklinikum Schleswig-Holstein
Kiel, Germany

How to reconcile novel reconstructive techniques with the need to radiate
Christine Solbach, MD, PhD
University Hospital Frankfurt
Frankfurt, Germany

EDUCATIONAL SESSION BLOCK #1C - Hemisfair Ballroom 3
New Agents Targeting HRD in Breast Cancer
Moderator: Erica Stringer-Reasor, MD
University of Alabama at Birmingham
Birmingham, AL

Pol-theta inhibitors in HRD tumors
Alan D. d'Andrea, MD
Dana-Farber Cancer Institute
Boston, MA

Mechanisms of sensitivity and resistance to HRD targeting agents in breast cancer - PARPi and beyond
Christopher Lord, DPhil
Institute of Cancer Research
London, United Kingdom

ATR inhibitors and PARP1 selective PARP inhibitors
Andrew Tutt, MM ChB, PhD
Institute of Cancer Research
London, United Kingdom

EDUCATIONAL SESSION BLOCK #1D - Stars at Night Ballroom 1&2
Predictive Value of Treatment Response and Residual Disease After Neoadjuvant Therapy
Moderator: Virginia Kaklamani, MD
UT Health San Antonio
San Antonio, TX

ER therapies
Cynthia X. Ma, MD, PhD
Washington University in St. Louis
St. Louis, MO

HER2
Luca Gianni, MD
Fondazione Michelangelo
Milano, Italy

Triple negative
Peter Schmid, MD, PhD
Bart's Cancer Institute
London, United Kingdom

SPECIAL SESSION #1 - Stars at Night Ballroom 1&2
Big Data and Health Equity
Moderators: Thelma Brown, BSc
University of Alabama at Birmingham
Birmingham, AL

Maimah Karmo, BS
Tigerlily Foundation
Aldie, VA

Charles Perou, PhD
University of North Carolina
Chapel Hill, NC

Patty Spears, BS
University of North Carolina at Chapel Hill
Raleigh, NC

Keynote Speakers:
Martin Mendoza, PhD
National Institutes of Health
Bethesda, MD

Barbara Seggara, D.H.Sc
University of Puerto Rico
San Juan, Puerto Rico

Panelists:
Rhea Blakey
FDA
Silver Spring, MD

Michael Crawford, MBA, MHLA
Howard University
Washington, DC

Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN

Martin Mendoza, PhD
National Institute of Health
Bethesda, MD

Charlotte Owens, MD
Takeda Pharmaceutical Company
Cambridge, MA

Barbara Seggara, D.H.Sc
University of Puerto Rico
San Juan, Puerto Rico

Jasmine Souers, BSc
The Missing Pink Breast Cancer Alliance
Jackson, FL

SPECIAL SESSION #2 - Hall 3
Tackling the Big Questions in Breast Cancer?
Chairs: 
Carlos Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
and
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

Panelists: 
Christine Ambrosone, PhD
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Fabrice André, MD, PhD
Gustave Roussy
Villejuif, France

Regina Barzilay, PhD
Massachusetts Institute of Technology
Cambridge, MA

Joan S. Brugge, PhD
Harvard Medical School
Boston, MA

Matthew J. Ellis, MD, PhD
AstraZeneca
Gaithersburg, MD

Nadia Harbeck, MD, PhD
LMU University Hospital
Munich, Germany

Yeon Hee Park, MD, PhD
Samsung Medical Center
Seoul, South Korea

Lori Pierce, MD
University of Michigan
Ann Arbor, MI

Patty Spears, BS
UNC Patient Advocates for Research Council
Chapel Hill, NC

Eric Winer, MD
Yale Cancer Center
New Haven, CT